Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29690180 | 0.83 | CYP1A2 (0.55) | HTR2AMAPK1KDM4ETDP1HTR2C | |
| SCHEMBL19869956 | 0.83 | GAA (0.66) | GAAMAPK1DRD2DRD4HRH2 | |
| SCHEMBL20545632 | 0.83 | CYP1A2 (0.55) | HTR2AMAPK1KDM4ETDP1HTR2C | |
| SCHEMBL25933538 | 0.81 | GAA (0.56) | GAADRD2DRD4HRH2DRD3 | |
| SCHEMBL19869938 | 0.78 | GAA (0.67) | GAADRD2DRD4HRH2DRD3 | |
| SCHEMBL19869944 | 0.77 | KDM4E (0.55) | HTR2AMAPK1KDM4EHTR2CTAAR1 | |
| SCHEMBL21550472 | 0.77 | HTT (0.56) | GAALMNAHTTACHE | |
| SCHEMBL25511834 | 0.76 | TRPV6 (0.49) | GAAMAPK1KDM4ETDP1MTNR1A | |
| SCHEMBL19869951 | 0.76 | PKM (0.47) | HTR2AMAPK1KDM4ELMNAMTNR1A | |
| SCHEMBL21538245 | 0.75 | KDM4E (0.67) | GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | GAA 4237/4885HTR2A 2363/4885MAPK1 611/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | GAA 4152/4885HTR2A 2265/4885MAPK1 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.